Neuroone Medical Technologies CORP Form 4 insider transactions

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 252 shares of common stock on August 31, 2024, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on August 31, 2024, to cover tax obligations.

David A. Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 2,239 shares of common stock on August 31, 2024, to cover tax obligations.

Paul Buckman, a director of NeuroOne Medical Technologies, acquired common stock and warrants on August 1, 2024.

Chief Technology Officer Steve Mertens disposed of 252 shares of NeuroOne Medical Technologies stock to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on July 31, 2024, to cover tax obligations.

David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 2,239 shares of common stock on July 31, 2024, to cover tax obligations.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 1,158 shares of common stock on June 30, 2024, to satisfy tax withholding obligations.

David Rosa, CEO and President of NeuroOne Medical Technologies, disposed of 4,697 shares of common stock on June 30, 2024, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 343 shares of common stock on June 30, 2024, to satisfy tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, sold 2,189 shares of common stock at $0.876 per share on June 6, 2024.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, sold 25,800 shares of common stock at an average price of $0.8784 on June 5, 2024.

Chief Technology Officer Steve Mertens disposed of 252 shares of NeuroOne Medical Technologies to cover tax obligations arising from a previous transaction.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on May 31, 2024, to cover tax obligations.

CEO David Rosa disposed of 2,239 shares of NeuroOne Medical Technologies to cover tax obligations arising from a previous transaction.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 252 shares of common stock on April 30, 2024, to satisfy tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on April 30, 2024, to satisfy tax withholding obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on April 30, 2024, to satisfy tax obligations related to equity awards.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 7,250 shares of common stock on April 21, 2024, to satisfy tax withholding obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 2,030 shares of common stock on April 21, 2024, to satisfy tax withholding obligations.

CEO David Rosa disposed of 19,673 shares of NeuroOne Medical Technologies to cover tax obligations related to vested restricted stock units.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 252 shares of common stock on March 31, 2024, to cover tax obligations.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on March 31, 2024, to cover tax obligations.

NeuroOne Medical Technologies CEO David A. Rosa disposed of 2,239 shares of common stock on March 31, 2024, to satisfy tax withholding obligations.

Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, disposed of 252 shares of common stock on February 29, 2024, to satisfy tax obligations.

NeuroOne Medical Technologies CEO David Rosa disposed of 2,239 shares of common stock on February 29, 2024, to cover tax obligations related to equity awards.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, disposed of 90 shares of common stock on February 29, 2024, to cover tax obligations.